Format

Send to

Choose Destination
Curr Opin Hematol. 2005 Mar;12(2):129-34.

New developments in iron chelators.

Author information

1
Harvard Medical School, Children's Hospital, Boston, MA 02115, USA. Melody.Cunningham@childrens.harvard.edu

Abstract

PURPOSE OF REVIEW:

For three decades, deferoxamine has been the only approved iron chelator. This drug has an extremely short-half life and is not orally absorbed; thus, a search has been ongoing for alternative chelators with less onerous delivery. Recently, several oral iron chelators and variations of deferoxamine to prolong the half-life have been developed. These and the methods of monitoring iron overload are the subjects of this review.

RECENT FINDINGS:

New chelators, combinations of chelators and regimens for known chelators and their safety and efficacy are being studied in important preclinical and clinical trials.

SUMMARY:

The care and clinical outcomes of patients with thalassemia and other iron-overload disorders may be markedly improved by recent discoveries and novel approaches to chelation therapy.

PMID:
15725903
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center